Apparatus

Under the terms of the collaboration agreement, GenKOre will receive up to US$300 million, including upfront fees, fees for exercising its option, and milestone payments for successfully reaching development and commercialisation milestones against two in vivo disease targets.

A new approach to cancer treatment!

Elahere, the first antibody-coupled drug (ADC) for refractory ovarian cancer, has received accelerated approval from the FDA, resulting in substantial tumour shrinkage in 31.7% of patients and complete tumour disappearance in 4.8%.

Misconceptions about how to treat a sore throat are fuelling the overuse of antibiotics, according to STAR research.

New therapy for lung cancer!

Scientists from MIT designed a microfluidic device to capture and count circulating plasma cells in small samples of blood. This technique can only be carried out through routine blood drawing, which is expected to reduce the pain of patients' myeloma testing.

H-Drugs in the leading international journal again!

Medical engineers at Walter Reed National Military Medical Center are using additive manufacturing to develop customized prosthetic solutions for veterans. In fact, the center is even operating a 3D Medical Application Center (3DAC). There, a team of specialized engineers and 3D printing technicians are developing customized equipment according to the requirements of veterans.

The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.

Ibuprofen belongs to antipyretic and analgesic, not cold medicine.